facilities, and marketing expenses as compared with the prior-year
-- Cash and cash equivalents were $97.7 million as of December 31, 2007,
compared with $44.2 million as of December 31, 2006 and $105.1
million as of September 30, 2007.
Financial Outlook for 2008
The Company anticipates 2008 cash expenses of approximately $40 million to $50 million, depending on the progress of various pre-clinical and clinical programs and the timing of its manufacturing scale up.
Halozyme management will host a pipeline update conference call tomorrow to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 888-463-4487 for domestic callers, or 706-679-5355 for international callers. A telephone replay will be available for 48 hours by dialing 800-642-1687 for domestic callers, or 706-645-9291 for international callers, and entering reservation number 21378327. The conference call will be broadcast live over the Internet at http://www.halozyme.com and will be available for 30 days.
HYLENEX recombinant (hyaluronidase human injection) is indicated as an
adjuvant to increase the absorption and dispersion of other injected drugs,
as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and
as an adjunct in subcutaneous urography for improving resorption of
radiopaque agents. Hyaluronidase is contraindicated in patients with
hypersensitivity to hyaluronidase enzyme or any other ingredients in the
formulation. Hyaluronidase should not be used to enhance the absorption and
dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX
recombinant if sensitization occurs. Hyaluronidase should not be applied
directly to the cornea, and should not be injected around infected or
|SOURCE Halozyme Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved